In vivo effects of imatinib mesylate on human haematopoietic progenitor cells

European Journal of Clinical Investigation

Volumn 36, Issue 6, 2006, Pages 402-408

  Agis, H ^a   Jaeger, E ^a   Doninger, B ^a   Sillaber, C ^a   Marosi, C ^a   Drach, J ^a   Schwarzinger, I ^a   Valent, P ^a   Oehler, L ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Circulating progenitors; CML; Haematopoiesis; Imatinib

Indexed keywords

IMATINIB;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; BRAIN TUMOR; CELL COUNT; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PRIORITY JOURNAL; SOLID TUMOR; THROMBOCYTOPENIA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 33646691022     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2006.01645.x     Document Type: Article

References (31)

1. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of BCR-ABL positive cells. Nat Med 1996 2 : 561 6.
2. Deininger MW, Goldman JM, Lydon NB, Melo JV. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL positive cells. Blood 1997 90 : 3197 204.
3. Kasper B, Fruehauf S, Schiedlmeier B, Buchdunger E, Ho AD, Zeller WJ. Favorable therapeutic index of a p210 (BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukaemia progenitors. Cancer Chemother Pharmacol 1999 44 : 433 8.
4. Marley SB, Davidson RJ, Lewis JL, Nguyen DX, Eades A, Parker S et al. Progenitor cells from patients with advanced phase chronic myeloid leukaemia respond to STI571 in vitro and in vivo. Leuk Res 2001 25 : 997 1002.
5. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukaemia. N Engl J Med 2001 344 : 1031 7.
6. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukaemia and lymphoblastic leukaemia with the Philadelphia chromosome. N Engl J Med 2001 344 : 1038 42.
7. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F et al. IRIS Investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. N Engl J Med 2003 348 : 994 1004.
8. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Haematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia. N Engl J Med 2002 346 : 645 52.
9. Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F et al. Imatinib induces durable haematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukaemia: results of a phase 2 study. Blood 2002 99 : 1928 37.
10. Sillaber C, Mayerhofer M, Agis H, Sagaster V, Mannhalter C, Sperr WR et al. Chronic myeloid leukaemia: pathophysiology, diagnostic parameters and current treatment concepts. Wien Klin Wochenschr 2003 115 : 485 504.
11. Sneed TB, Kantarjian HM, Talpaz M, O'Brien S, Rios MB, Bekele BN et al. The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukaemia in chronic phase. Cancer 2004 100 : 116 21.
12. Demetri GD, von Mehren M, Blanke CD, van den Abbeele AD, Eisenberg B, Roberts PJ. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumours. N Engl J Med 2002 347 : 472 80.
13. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G et al. Imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumours. Clin Cancer Res 2002 8 : 3034 8.
14. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004 364 : 1127 34.
15. Blanke CD, Corless CL. State-of-the art therapy for gastrointestinal stromal tumours. Cancer Invest 2005 23 : 274 80.
16. Cortes J, Kantarjian H. Beyond chronic myelogenous leukaemia: Potential role for imatinib in Philadelphia-negative myeloproliferative disorders. Cancer 2004 100 : 2064 78.
17. Oehler L, Jaeger E, Eser A, Sillaber C, Gisslinger H, Geissler K. Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythaemia vera in vitro. Blood 2003 102 : 2240 2.
18. Silver RT. Imatinib mesylate (Gleevec™) reduces phlebotomy requirements in polycythaemia vera. Leukemia 2003 17 : 1186 7.
19. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R. Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukaemia through reversal of abnormally increased proliferation. Blood 2002 99 : 3792 800.
20. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukaemia are insensitive to STI571 in vitro. Blood 2002 99 : 319 25.
21. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Saywers CL et al. Persistence of malignant haematopoietic progenitors in chronic myelogenous leukaemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003 101 : 4701 7.
22. Prejzner W, Knopinska-Posluszny W, Mikolaczuk J, Langowska B, Hellmann A. Modification of the clonogenic capacity of bone marrow cells from normal individuals by the tyrosine kinase inhibitor STI571. Clin Lab Haem 2003 25 : 293 6.
23. Bartolovic K, Balabanov S, Hartmann U, Komor M, Boehmler M, Bühring HJ et al. Inhibitory effect of imatinib on normal progenitor cells in vitro. Blood 2004 103 : 523 9.
24. Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia 2003 17 : 1713 21.
25. Appel S, Boehmler AM, Grunebach F, Muller MR, Rupf A, Weck MM et al. Imatinib mesylate affects the development and function of dentritic cells generated from CD34+ peripheral blood progenitor cells. Blood 2004 103 : 538 44.
26. Seggewiss R, Lore K, Greiner E, Magnusson MK, Price DA, Douek DC et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005 105 : 2473 9.
27. Dewar A, Cambareri AC, Zannettino ACW, Miller BL, Doherty KV, Hughes TP et al. Macrophage colony stimulating factor receptor, c-fms, is a novel target of imatinib. Blood 2005 105 : 3127 32.
28. Appel S, Rupf A, Weck MW, Schoor O, Brümmendorf TH, Weinschenk T et al. Effects of imatinib on monocytes-derived dentritic cells are mediated by inhibition of nuclear factor-kB and AKT signaling pathways. Clin Cancer Res 2005 11 : 1928 40.
29. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000 295 : 139 45.
30. Oehler L, Foedinger M, Koeller M, Kollars M, Reiter E, Bohle B et al. Interleukin-10 inhibits spontaneous colony-forming-unit granulocyte-macrophage growth from human peripheral blood mononuclear cells by suppression of endogeneous granulocyte-macrophage colony-stimulating factor release. Blood 1997 89 : 1147 53.
31. Socinski MA, Cannistra SA, Elias A, Antman KH, Schnipper L, Griffin JD. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988 28 : 1194 8.